Road to early detection of pancreatic cancer: Attempts to utilize epigenetic biomarkers

Cancer Letters

Volumn 342, Issue 2, 2014, Pages 231-237

  Fukushige, Shinichi ^a,b   Horii, Akira ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

DNA methylation; Early detection; MiRNA; Pancreatic cancer; Satellite repeats

Indexed keywords

HISTONE H3; HISTONE H4; MICRORNA; TRANSCRIPTION FACTOR EZH2;

CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; EARLY DIAGNOSIS; EPIGENETICS; GENOMIC INSTABILITY; HETEROCHROMATIN; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; LONG INTERSPERSED REPEAT; MUCINOUS CYSTIC NEOPLASM; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS CANCER; PRIORITY JOURNAL; SHORT SURVEY; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

EID: 84888201440     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.03.022     Document Type: Review

References (85)

1. Ghaneh P., Costello E., Neoptolemos J.P. Biology and management of pancreatic cancer. Gut 2007, 56:1134-1152.
2. Rulyak S.J., Lowenfels A.B., Maisonneuve P., Brentnall T.A. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 2003, 124:1292-1299.
3. Klein A.P., Hruban R.H., Brune K.A., Petersen G.M., Goggins M. Familial pancreatic cancer. Cancer J. 2001, 7:266-273.
4. Amundadottir L.T., Thorvaldsson S., Gudbjartsson D.F., Sulem P., Kristjansson K., Arnason S., Gulcher J.R., Bjornsson J., Kong A., Thorsteinsdottir U., Stefansson K. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med. 2004, 1:65.
5. Klein A.P., Brune K.A., Petersen G.M., Goggins M., Tersmette A.C., Offerhaus G.J., Griffin C., Cameron J.L., Yeo C.J., Kern S., Hruban R.H. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004, 64:2634-2638.
6. Lowenfels A.B., Maisonneuve P., Cavallini G., Ammann R.W., Lankisch P.G., Andersen J.R., Dimagno E.P., Andrén-Sandberg A., Domellöf L. The International Pancreatitis Study Group, Pancreatitis and the risk of pancreatic cancer. New Engl. J. Med. 1993, 328:1433-1437.
7. Lowenfels A.B., Maisonneuve P., DiMagno E.P., Elitsur Y., Gates L.K.Jr., Perrault J., Whitcomb D.C. The International Hereditary Pancreatitis Study Group, Hereditary pancreatitis and the risk of pancreatic cancer. J. Natl. Cancer Inst. 1997, 89:442-446.
8. Malka D., Hammel P., Maire F., Rufat P., Madeira I., Pessione F., Lévy P., Ruszniewski P. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002, 51:849-852.
9. Brentnall T.A., Bronner M.P., Byrd D.R., Haggitt R.C., Kimmey M.B. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann. Intern. Med. 1999, 131:247-255.
10. Canto M.I., Goggins M., Yeo C.J., Griffin C., Axilbund J.E., Brune K., Ali S.Z., Jaqannath S., Petersen G.M., Fishman E.K., Piantadosi S., Giardiello F.M., Hruban R.H. Screening for pancreatic neoplasia in high risk individuals: an EUS-based approach. Clin. Gastroenterol. Hepatol. 2004, 2:606-621.
11. Charpentier K.P., Brentnall T.A., Bronner M.P., Byrd D., Marsh C. A new indication for pancreas transplantation: high grade pancreatic dysplasia. Clin. Transplant. 2004, 18:105-107.
12. Buchholz M., Kestler H.A., Bauer A., Böck W., Rau B., Leder G., Kratzer W., Bommer M., Scarpa A., Schilling M.K., Adler G., Hoheisel J.D., Gress T.M. Specialized DNA arrays for the differentiation of pancreatic tumors. Clin. Cancer Res. 2005, 11:8048-8054.
13. Fukushige S., Furukawa T., Satoh K., Sunamura M., Kobari M., Koizumi M., Horii A. Loss of chromosome 18q is an early event in pancreatic ductal tumorigenesis. Cancer Res. 1998, 58:4222-4226.
14. Goggins M. Molecular markers of early pancreatic cancer. J. Clin. Oncol. 2005, 23:4524-4531.
15. Yanagisawa A., Ohtake K., Ohashi K., Hori M., Kitagawa T., Sugano H., Kato Y. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res. 1993, 53:953-956.
16. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat. Rev. Cancer 2004, 4:143-153.
17. Kimura M., Abe T., Sunamura M., Matsuno S., Horii A. Detailed deletion mapping on chromosome arm 12q in human pancreatic adenocarcinoma: identification of a 1-cM region of common allelic loss. Genes Chromosomes Cancer 1996, 17:88-93.
18. Fukushige S., Waldman F.M., Kimura M., Abe T., Furukawa T., Sunamura M., Kobari M., Horii A. Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer 1997, 19:161-169.
19. Sjöblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
20. Beerenwinkel N., Antal T., Dingli D., Traulsen A., Kinzler K.W., Velculescu V.E., Vogelstein B., Nowak M.A. Genetic progression and the waiting time to cancer. PLoS Comput. Biol. 2007, 3:e225.
21. Jones S., Zhang X., Parsons D.W., Lin J.C.-H., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.-M., Fu B., Lin M.-T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
22. Campbell P.J., Yachida S., Mudie L.J., Stephens P.J., Pleasance E.D., Stebbings L.A., Morsverger L.A., Latimer C., McLaren S., Lin M.-L., McBride D.J., Varela I., Nik-Zainal S.A., Leroy C., Jia M., Menzies A., Butler A.P., Teague J.W., Griffin C.A., Burton J., Swerdlow H., Quail M.A., Stratton M.R., Iacobuzio-Donahue C., Futreal P.A. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010, 467:1109-1113.
23. Yachida S., Jones S., Bozic I., Antal T., Leary R., Fu B., Kamiyama M., Hruban R.H., Eshleman J.R., Nowak M.A., Velculescu V.E., Kinzler K.W., Vogelstein B., Iacobuzio-Donahue C.A. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467:1114-1117.
24. Meza R., Jeon J., Moolgavkar S.H., Luebeck E.G. Age-specific incidence of cancer: phases, transitions, and biological implications. Proc. Natl. Acad. Sci. USA 2008, 105:16284-16289.
25. Laird P.W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 2003, 3:253-266.
26. Miyamoto K., Ushijima T. Diagnostic and therapeutic applications of epigenetics. Jpn. J. Clin. Oncol. 2005, 35:293-301.
27. Ushijima T. Epigenetic field for cancerization. J. Biochem. Mol. Biol. 2007, 40:142-150.
28. Schuebel K.E., Chen W., Cope L., Glockner S.C., Suzuki H., Yi J.-M., Chan T.A., Neste L.V., Crikinge W.V., van den Bosch S., van Engeland M., Ting A.H., Jair K., Yu W., Toyota M., Imai K., Ahuja N., Herman J.G., Baylin S.B. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 2007, 3:e157.
29. Sakai T., Toguchida J., Ohtani N., Yandell D.W., Rapaport J.M., Dryja T.P. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am. J. Hum. Genet. 1991, 48:880-888.
30. Schutte M., Hruban R.H., Geradts J., Maynard R., Hilgers W., Rabindran S.K., Moskaluk C.A., Hahn S.A., Schwarte-Waldhoff I., Schmiegel W., Baylin S.B., Kern S.E., Herman J.G. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997, 57:3126-3130.
31. Ueki T., Toyota M., Sohn T., Yeo C.J., Issa J.P., Hruban R.H., Goggins M. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000, 60:1835-1839.
32. Nakata B., Wang Y.Q., Yashiro M., Nishioka N., Tanaka H., Ohira M., Ishikawa T., Nishino H., Hirakawa K. Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin. Cancer Res. 2002, 8:2536-2540.
33. Sato N., Fukushima N., Maehara N., Matsubayashi H., Koopmann J., Su G.H., Hruban R.H., Goggins M. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003, 22:5021-5030.
34. Infante J.R., Matsubayashi H., Sato N., Tonascia J., Klein A.P., Riall T.A., Yeo C., Iacobuzio-Donahue C., Goggins M. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J. Clin. Oncol. 2007, 25:319-325.
35. Xu S., Furukawa T., Kanai N., Sunamura M., Horii A. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J. Hum. Genet. 2005, 50:159-167.
36. Sato N., Fukushima N., Chang R., Matsubayashi H., Goggins M. Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. Gastroenterology 2006, 130:548-565.
37. Dammann R., Schagdarsurengin U., Liu L., Otto N., Gimm O., Dralle H., Boehm B.O., Pfeifer G.P., Hoang-Vu C. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 2003, 22:3806-3812.
38. Matsubayashi H., Sato N., Fukushima N., Yeo C.J., Walter K.M., Brune K., Sahin F., Hruban R.H., Goggins M. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age- related phenomenon in gastrointestinal tissues. Clin. Cancer Res. 2003, 9:1446-1452.
39. Sato N., Parker A.R., Fukushima N., Miyagi Y., Iacobuzio-Donahue C.A., Eshleman J.R., Goggins M. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 2005, 24:850-858.
40. Wada M., Yazumi S., Takaishi S., Hasegawa K., Sawada M., Tanaka H., Ida H., Sakakura C., Ito K., Chiba T. Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines. Oncogene 2004, 23:2401-2407.
41. Nomoto S., Kinoshita T., Mori T., Kato K., Sugimoto H., Kanazumi N., Takeda S., Nakao A. Adverse prognosis of epigenetic inactivation in RUNX3 gene at 1p36 in human pancreatic cancer. Br. J. Cancer 2008, 98:1690-1695.
42. Fukushima N., Sato N., Sahin F., Su G.H., Hruban R.H., Goggins M. Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br. J. Cancer 2003, 89:338-343.
43. Jansen M., Fukushima N., Rosty C., Walter K., Altink R., Heek T.V., Hruban R., Offerhaus J.G., Goggins M. Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanINs. Cancer Biol. Ther. 2002, 1:293-296.
44. Ueki T., Toyota M., Skinner H., Walter K.M., Yeo C.J., Issa J.P., Hruban R.H., Goggins M. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res. 2001, 61:8540-8546.
45. Fukushima N., Sato N., Ueki T., Rosty C., Walter K.M., Wilentz R.E., Yeo C.J., Hruban R.H., Goggins M. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am. J. Pathol. 2002, 160:1573-1581.
46. Sato N., Fukushima N., Maitra A., Matsubayashi H., Yeo C.J., Cameron J.L., Hruban R.H., Goggins M. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res. 2003, 63:3735-3742.
47. Sato N., Fukushima N., Matsubayashi H., Iacobuzio-Donahue C.A., Yeo C.J., Goggins M. Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma. Cancer 2006, 107:251-257.
48. Omura N., Li C.P., Li A., Hong S.M., Walter K., Jimeno A., Hidalgo M., Goggins M. Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol. Ther. 2008, 7:1146-1156.
49. Sato Y., Horii A., Fukushige S. Microarray coupled with methyl-CpG targeted transcriptional activation (MeTA-array) identifies hypermethylated genes containing the stringent criteria of CpG islands at high frequency. Epigenetics 2011, 6:752-759.
50. Shimizu H., Horii A., Sunamura M., Motoi F., Egawa S., Unno M., Fukushige S. Identification of epigenetically silenced genes in human pancreatic cancer by a novel method "microarray coupled with methyl-CpG targeted transcriptional activation" (MeTA-array). Biochem. Biophys. Res. Commun. 2011, 411:162-167.
51. Rosty C., Ueki T., Argani P., Jansen M., Yeo C.J., Cameron J.L., Hruban R.H., Goggins M. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am. J. Pathol. 2002, 160:45-50.
52. Sato N., Maitra A., Fukushima N., van Heek N.T., Matsubayashi H., Iacobuzio-Donahue C.A., Rosty C., Goggins M. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res. 2003, 63:4158-4166.
53. Sato N., Fukushima N., Matsubayashi H., Goggins M. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene 2004, 23:1531-1538.
54. Matsubayashi H., Canto M., Sato N., Klein A., Abe T., Yamashita K., Yeo C.J., Kalloo A., Hruban R., Goggins M. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res. 2006, 66:1208-1217.
55. Wilentz R.E., Iacobuzio-Donahue C.A., Argani P., McCarthy D.M., Parsons J.L., Yeo C.J., Kern S.E., Hruban R.H. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 2000, 60:2002-2006.
56. Furukawa T., Fujisaki R., Yoshida Y., Kanai N., Sunamura M., Abe T., Takeda K., Matsuno S., Horii A. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod. Pathol. 2005, 18:1034-1042.
57. Sato N., Matsubayashi H., Abe T., Fukushima N., Goggins M. Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin. Cancer Res. 2005, 11:4681-4688.
58. Sato N., Ueki T., Fukushima N., Iacobuzio-Donahue C.A., Yeo C.J., Cameron J.L., Hruban R.H., Goggins M. Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 2002, 123:365-372.
59. Hong S.M., Kelly D., Griffith M., Omura N., Li A., Li C.P., Hruban R.H., Goggins M. Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Mod. Pathol. 2008, 21:1499-1507.
60. Sato N., Fukushima N., Hruban R.H., Goggins M. CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod. Pathol. 2008, 21:238-244.
61. Kim S.G., Wu T.T., Lee J.H., Yun Y.K., Issa J.P., Hamilton S.R., Rashid A. Comparison of epigenetic and genetic alterations in mucinous cystic neoplasm and serous microcystic adenoma of pancreas. Mod. Pathol. 2003, 16:1086-1094.
62. Lodygin D., Tarasov V., Epanchintsev A., Berking C., Knyazeva T., Körner H., Knyazev P., Diebold J., Hermeking H. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008, 7:2591-2600.
63. Lee K.H., Lotterman C., Karikari C., Omura N., Feldmann G., Habbe N., Goggins M.G., Mendell J.T., Maitra A. Epigenetic silencing of microRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 2009, 9:293-301.
64. Zhang S., Hao J., Xie F., Hu X., Liu C., Tong J., Zhou J., Wu J., Shao C. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis 2011, 32:1183-1189.
65. Hanoun N., Delpu Y., Suriawinata A.A., Bournet B., Bureau C., Selves J., Tsongalis G.J., Dufresne M., Buscail l., Cordelier P., Torrisani J. The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin. Chem. 2010, 56:1107-1118.
66. Dillhoff M., Liu J., Frankel W., Croce C., Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J. Gastrointest. Surg. 2008, 12:2171-2176.
67. Habbe N., Koorstra J.B., Mendell J.T., Offerhaus G.J., Ryu J.K., Feldmann G., Mullendore M.E., Goggins M.G., Hong S.M., Maitra A. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol. Ther. 2009, 8:340-346.
68. Ryu J.K., Hong S.M., Karikari C.A., Hruban R.H., Goggins M.G., Maitra A. Aberrant microRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology 2010, 10:66-73.
69. Li A., Omura N., Hong S.-M., Vincent A., Walter K., Griffith M., Borges M., Goggins M. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res. 2010, 70:5226-5237.
70. Park S.M., Gaur A.B., Lengyel E., Peter M.E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008, 22:894-907.
71. Korpal M., Lee E.S., Hu G., Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 2008, 283:14910-14914.
72. Ting D.T., Lipson D., Paul S., Brannigan B.W., Akhavanfard S., Coffman E.J., Contino G., Deshpande V., Iafrate A.J., Letovsky S., Rivera M.N., Bardeesy N., Maheswaran S., Haber D.A. Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science 2011, 331:593-596.
73. Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc. Natl. Acad. Sci. USA 2006, 103:5947-5952.
74. Zhu Q., Pao G.M., Huynh A.M., Suh H., Tonnu N., Nederlof P.M., Gage F.H., Verma I.M. BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature 2011, 477:179-184.
75. Fahrner J.A., Eguchi S., Herman J.G., Baylin S.B. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 2002, 62:7213-7218.
76. Ballestar E., Paz M.F., Valle L., Wei S., Fraga M.F., Espada J., Cigudosa J.C., Huang T.H., Esteller M. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J. 2003, 22:6335-6345.
77. Viré E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., Morey L., Van Eynde A., Bernard D., Vanderwinden J.M., Bollen M., Esteller M., Di Croce L., de Launoit Y., Fuks F. The polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871-874.
78. WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 2000, 97:10014-10019.
79. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., Iyer N.G., Pérez-Rosado A., Calvo E., Lopez J.A., Cano A., Calasanz M.J., Colomer D., Piris M.Á., Ahn N., Imhof A., Caldas C., Jenuwein T., Esteller M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37:391-400.
80. Orlando V., Paro R. Mapping polycomb-repressed domains in the bithorax complex using in vivo formaldehyde cross-linked chromatin. Cell 1993, 75:1187-1198.
81. Schones D.E., Zhao K. Genome-wide approaches to studying chromatin modifications. Nat. Rev. Genet. 2008, 9:179-191.
82. Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., Kurdistani S.K. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
83. Ougolkov A.V., Bilim V.N., Billadeau D.D. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin. Cancer Res. 2008, 14:6790-6796.
84. Toll A.D., Dasgupta A., Potoczek M., Yeo C.J., Kleer C.G., Brody J.R., Witkiewicz A.K. Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Hum. Pathol. 2010, 41:1205-1209.
85. O. Nakahara, H. Takamori, M. Iwatsuki, Y. Baba, Y. Sakamoto, H. Tanaka, A. Chikamoto, K. Horino, T. Beppu, K. Kanemitsu, Y. Honda, K. Iyama, H. Baba, Carcinogenesis of intraductal papillary mucinous neoplasm of the pancreas: loss of microRNA-101 promotes overexpression of histone methyltransferase EZH2, Ann. Surg. Oncol. Epub ahead of print.